Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients

E A Lien, K Wester, P E Lønning, E Solheim, P M Ueland, E A Lien, K Wester, P E Lønning, E Solheim, P M Ueland

Abstract

We determined the amount of tamoxifen, N-desmethyltamoxifen (metabolite X), N-desdimethyltamoxifen (metabolite Z), and hydroxylated metabolites (Y, B, BX) in brain metastases from breast cancer and in the surrounding brain tissues. Specimens were collected from the breast cancer patients who received tamoxifen for 7-180 days and with the last dose taken within 28 h before surgical removal of the tumour. The concentrations of tamoxifen and its metabolites were up to 46-fold higher in the brain metastatic tumour and brain tissue than in serum. Metabolite X was the most abundant species followed by tamoxifen and metabolite Z. Small but significant amounts of the hydroxylated metabolites, trans-1(4-beta-hydroxyethoxyphenyl)-1,2-diphenylbut-1-ene (metabolite Y), 4-hydroxytamoxifen (metabolite B) and 4-hydroxy-N-desmethyltamoxifen (metabolite BX) were detected in most specimens. The ratios between the concentrations of tamoxifen and various metabolites were similar in tumour, brain and serum. This is the first report on the distribution of tamoxifen and metabolites into human brain and brain tumour, and the data form a basis for further investigation into the therapeutic effects of tamoxifen on brain metastases from breast cancer.

References

    1. J Nerv Ment Dis. 1976 Oct;163(4):267-75
    1. Surg Clin North Am. 1964 Jun;44:865-72
    1. Cancer. 1981 Jul 15;48(2):384-94
    1. Cancer Treat Rep. 1981 May-Jun;65(5-6):477-83
    1. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):793-5
    1. Lancet. 1981 Oct 3;2(8249):745-6
    1. Clin Oncol. 1981 Dec;7(4):291-301
    1. J Steroid Biochem. 1982 Jan;16(1):1-13
    1. Acta Pharmacol Toxicol (Copenh). 1982 Mar;50(3):161-8
    1. Cancer. 1983 Dec 15;52(12):2349-54
    1. Pharmacol Rev. 1984 Dec;36(4):245-76
    1. Cancer. 1985 Aug 15;56(4):880-2
    1. Biochem Pharmacol. 1985 Oct 15;34(20):3649-53
    1. Cancer. 1986 Aug 15;58(4):832-9
    1. Cancer Chemother Pharmacol. 1986;18(1):21-3
    1. Ann Neurol. 1986 Oct;20(4):544
    1. Cancer Treat Rev. 1987 Mar;14(1):1-28
    1. Clin Chem. 1987 Sep;33(9):1608-14
    1. Cancer. 1987 Nov 15;60(10):2559-62
    1. Cancer Res. 1988 Apr 15;48(8):2304-8
    1. Eur J Drug Metab Pharmacokinet. 1987 Oct-Dec;12(4):263-5
    1. Cancer Res. 1988 Jul 1;48(13):3626-9
    1. Breast Cancer Res Treat. 1988 Sep;12(1):83-6
    1. J Steroid Biochem. 1988 Oct;31(4B):665-9
    1. J Steroid Biochem. 1988 Oct;31(4B):671-6
    1. Cancer Res. 1989 Apr 15;49(8):2175-83
    1. Pharmacol Toxicol. 1989 Apr;64(4):373-7
    1. Cancer Res. 1989 Nov 15;49(22):6295-9
    1. Biochim Biophys Acta. 1989 Nov 20;1014(2):162-72
    1. Cancer Chemother Pharmacol. 1990;25(5):382-3
    1. Ann N Y Acad Sci. 1990;595:106-16
    1. J Pharmacol Exp Ther. 1964 Jan;143:14-22
    1. Cancer. 1979 Nov;44(5):1913-8

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi